Core Viewpoint - Fortinet, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its business operations and financial performance during the Class Period from November 8, 2024, to August 6, 2025 [1][4]. Financial Performance - On August 6, 2025, Fortinet reported its Q2 2025 financial results, indicating that it was "approximately 40% to 50% of the way through the 2026 firewall upgrade cycle" [2]. - The company provided weaker-than-expected revenue guidance for Q3 2025, projecting revenue between $1.67 billion and $1.73 billion [2]. Stock Price Impact - Following the release of the financial results, Fortinet's stock price dropped by $21.28, or 22%, closing at $75.30 per share on August 7, 2025 [3]. Allegations in the Lawsuit - The lawsuit claims that Fortinet's management made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects [4]. - Specific allegations include: - Misrepresentation of the profitability of the refresh cycle, which was said to consist of old products that were a "small percentage" of the business [4]. - Lack of clarity regarding the number of FortiGate firewalls eligible for upgrades [4]. - Misleading investors about the momentum of the refresh cycle, which was pushed through more quickly than communicated [4]. - Overall, the positive statements made by the company were deemed materially misleading and lacked a reasonable basis [4]. Legal Action Details - Investors who purchased Fortinet common stock during the Class Period can file a lead plaintiff motion by November 21, 2025 [5].

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, alleging misleading representations regarding its financial health and growth prospects, following a significant stock price decline after its earnings report in August [1][4]. Summary by Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., focuses on the period from May 7, 2025, to August 5, 2025, claiming that LifeMD made false statements, particularly during its first-quarter results announcement on May 6, 2025, when it raised its revenue and adjusted EBITDA guidance [2][4]. - The complaint asserts that LifeMD's optimistic outlook regarding its competitive position in virtual obesity care and performance from its RexMD brand was misleading, as it did not disclose significant operational challenges [2][3]. Financial Performance and Stock Impact - LifeMD's alleged deception became apparent on August 5, 2025, when it reported second-quarter results that missed revenue and earnings per share estimates, leading to a reduction in its full-year guidance. The management attributed this to "temporary elevated customer acquisition costs" and issues with patient refunds [4]. - Following the earnings announcement, LifeMD's stock price dropped by over 44% the next day, reflecting investor reaction to the disclosed operational issues [4]. Investor Recovery Opportunity - The lawsuit provides an opportunity for investors who suffered substantial losses during the specified period to seek recovery of damages [5]. - Hagens Berman, the firm investigating these claims, is looking into whether LifeMD was aware of but failed to disclose key operational problems [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Unicycive Therapeutics, Inc. securities during the class period from March 29, 2024, to June 27, 2025, about the lead plaintiff deadline of October 14, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the specified deadline [2]. - The lawsuit alleges that Unicycive made false and misleading statements regarding its compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and recognition in the field [3].

Core Points - Rosen Law Firm is reminding investors who purchased Dow Inc. securities between January 30, 2025, and July 23, 2025, about the lead plaintiff deadline of October 28, 2025 [1][2] - Investors may be entitled to compensation through a contingency fee arrangement without any out-of-pocket costs [1][2] Case Details - The lawsuit alleges that Dow made false and misleading statements regarding its ability to handle macroeconomic and tariff-related challenges, overstating its financial flexibility to support dividends [4] - It is claimed that the negative impacts of competitive pressures, softening global sales, and product oversupply were understated, leading to materially false public statements [4] - The lawsuit asserts that when the true details became known, investors suffered damages [4] Legal Representation - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [3] - Rosen Law Firm has a history of significant settlements and has been recognized for its performance in securities class actions [3]

Core Insights - Snap Inc. shares declined by 6.6% following Mizuho's initiation of coverage with a Neutral rating and a $9 price target, describing the company as a "show-me story" due to weak feedback from its advertising channels [1][2] Legal Issues - A federal securities class action lawsuit has been filed against Snap and certain senior executives, alleging that the company misrepresented the performance and growth prospects of its digital advertising platform [2][6] - The lawsuit claims that Snap experienced significant negative consequences from an "execution error" related to a recent change in its ad platform, which was not disclosed to investors during the Class Period [6][11] - The alleged deception became apparent on August 5, 2025, when Snap reported Q2 2025 results, admitting to a change that caused campaigns to clear at substantially reduced prices, leading to a slowdown in ad revenue growth from 9% in Q1 to just 1% in April [7][11] Class Action Details - The class action lawsuit covers investors who purchased shares between April 29, 2025, and August 5, 2025 [8][10] - Hagens Berman, a shareholder rights firm, is investigating the claims and encourages affected investors to come forward [9][12]

NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of WPP plc (NYSE: WPP). Shareholders who purchased shares of WPP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/wpp-plc-loss-submission-form/?id=171660&from=3 CLASS PERIOD: February 27, 2025 to July 8, 2025 ...

Core Viewpoint - A class action lawsuit has been filed against Molina Healthcare, Inc. regarding allegations of securities fraud and unlawful business practices [1][2]. Financial Performance - On July 7, 2025, Molina reported second quarter adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [2]. - The company cut its full-year 2025 adjusted earnings per share guidance by 10.2% at the midpoint, revising it from at least $24.50 per share to a range of $21.50 to $22.50 per share [2]. - Molina's stock price fell by $6.97 per share, or 2.9%, closing at $232.61 on July 7, 2025, following the earnings announcement [2]. - On July 23, 2025, Molina further reduced its full-year 2025 earnings guidance, now expecting adjusted earnings to be no less than $19.00 per diluted share, representing a 13.6% cut from the previous guidance [2]. - The company's GAAP net income for the second quarter was reported at $4.75 per diluted share, an 8% decrease year over year [2]. - Molina also cut its full-year 2025 GAAP net income guidance by 27% to $912 million, attributing the results to a challenging medical cost trend environment [2]. - Following this announcement, Molina's stock price dropped by $32.03 per share, or 16.84%, closing at $158.22 on July 24, 2025 [2].

Core Viewpoint - The Molina Healthcare class action lawsuit alleges that the company and its executives violated the Securities Exchange Act of 1934 by failing to disclose critical adverse information regarding its financial health and operational challenges during the specified class period [1][4]. Group 1: Class Action Details - The class action lawsuit is titled Hindlemann v. Molina Healthcare, Inc., and covers purchasers of Molina Healthcare securities from February 5, 2025, to July 23, 2025, with a deadline of December 2, 2025, for seeking lead plaintiff status [1]. - The lawsuit claims that Molina Healthcare did not disclose material facts about its medical cost trend assumptions and the dislocation between premium rates and medical costs [4]. Group 2: Financial Performance and Impact - On July 7, 2025, Molina Healthcare reported adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines, leading to a 10.2% cut in earnings guidance [5]. - Following the financial results announcement on July 23, 2025, Molina Healthcare reported a GAAP net income of $4.75 per diluted share for Q2 2025, an 8% decrease year-over-year, and revised its full-year 2025 adjusted earnings guidance to no less than $19.00 per diluted share [6]. Group 3: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Molina Healthcare securities during the class period to seek lead plaintiff status, which involves directing the class action lawsuit on behalf of all class members [7]. - Investors are not required to serve as lead plaintiff to share in any potential recovery from the lawsuit [7]. Group 4: Company Overview - Molina Healthcare provides managed healthcare services primarily to low-income families and individuals under Medicaid and Medicare programs [3].

, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH). NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of LNTH during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is November 10, 2025. There is no cost or obligation to you to participate in this cas ...

, /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Lantheus class action lawsuit – captioned Margolis v. Lantheus Holdings, Inc., No. 25-cv-07491 (S.D.N.Y.) – seeks to represent purchasers or acquirers of Lantheus Holdings, Inc. (NASDAQ: LNTH) securities and charges Lantheus as well as certain of Lantheus's executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Lantheus class action l ...